Diversified Healthcare Trust 2025年季度报告

QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2025OR TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of Principal Executive Offices) (Zip Code) in Rule12b-2 of the Exchange Act. Large accelerated filer☐ Non-accelerated filer☐Smaller reporting companyEmerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ March31, 2025INDEX Investments in unconsolidated joint ventures133,797Assets of properties held for sale79,737Cash and cash equivalents302,577 Liabilities and Equity Note 1.Basis of Presentation The accompanying condensed consolidated financial statements of Diversified Healthcare Trust and its subsidiaries, or DHC, we, us, orour, are unaudited.Certain information and disclosures required by U.S. generally accepted accounting principles, or GAAP, for completefinancial statements have been condensed or omitted.We believe the disclosures made are adequate to make the information presented notmisleading.However, the accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes contained in our Annual Report on Form 10-K for the year ended December31, 2024, or our Annual Report. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement of resultsfor the interim period have been included. All intercompany transactions and balances with or among our consolidated subsidiaries have beeneliminated.Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year. Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU No. 2023-09, which requires public entities to enhance theirannual income tax disclosures by requiring: (i) consistent categories and greater disaggregation of information in the rate reconciliation, and (ii) Disclosures (Subtopic 220-40): Disaggregation of Income Statements Expenses, or ASU No. 2024-03, which requires public entities to disclose specific expense categories such as employee compensation, depreciation and intangible asset amortization. These details must be presented ina tabular format in the notes to condensed consolidated financial statements for both interim and annual reporting periods. ASU 2024-03 isrequired to be applied prospectively but can be applied retrospectively, and is effective for the first annual reporting periods beginning after As of March31, 2025, we owned343properties located in34states and Washington, D.C., including11properties classified as held for sale andtwoclosed senior living communities, and we owned an equity interest in each oftwounconsolidated joint ventures that own medicaloffice and life science properties located infivestates.Dispositions: 6 for these properties are included in continuing operations through the date of sale of such properties in our condensed consolidated statementsof comprehensive income (loss). StateType of PropertyPropertiesSales PriceGain on SaleJanuary 2025DelawareSenior Living (SHOP)1$2,900$January 2025CaliforniaLife Science3159,025February 2025ArizonaLife Science116,800(1) March 2025Connecticut We used aggregate net proceeds of $299,158from the sales of these properties to partially redeem our outstanding senior secured notes due 2026.As of March31, 2025, we had11properties classified as held for sale in our condensed consolidated balance sheet as follows:SegmentNumber of PropertiesReal Estate Properties, N The net proceeds from the sale ofoneof these properties are required to be used to partially redeem our outstanding senior secured notes due 2026, ifthe sale of that property is completed. We expect to sell that property during the fourth quarter of 2025 for a sales price of $6,500, excluding closingcosts.Subsequent to March31, 2025, we soldoneproperty for a sales price of $11,150, excluding closing costs. As of May2, 2025, we had19properties under agreements or letters of intent to sell for an aggregate sales price of $115,773, excluding closing costs. The net proceeds from Impairment: We regularly evaluate our assets for indicators of impairment. Impairment indicators may include declining tenant or resident occupancy,weak or declining profitability from the property, decreasing tenant cash flows or liquidity, our decision to dispose of an asset before the end ofits estimated useful life and legislative, market or industry changes that could permanently reduce the value of an asset. If indicators ofimpairment are prese